FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.

Creative Commons License

Bengoa S. Y., Ataseven E., Kizmazoglu D., Yenigurbuz F. D., Erdem M., ÖREN H.

Turkish journal of haematology : official journal of Turkish Society of Haematology, cilt.34, sa.1, ss.46-51, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjh.2015.0411
  • Dergi Adı: Turkish journal of haematology : official journal of Turkish Society of Haematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.46-51
  • Anahtar Kelimeler: Relapsed/refractory leukemia, FLAG regimen, Chemotherapy, Childhood, ACUTE MYELOGENOUS LEUKEMIA, COLONY-STIMULATING FACTOR, ACUTE MYELOID-LEUKEMIA, RELAPSED ACUTE-LEUKEMIA, HIGH-DOSE CYTARABINE, G-CSF, RANDOMIZED-TRIAL, FLUDARABINE, CHILDHOOD, THERAPY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.